WA
HRTX icon

Wealth Alliance’s Heron Therapeutics HRTX Stock Holding History

Wealth Alliance’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32,000
Closed -$40.3K – 573
2025
Q3 		$40.3K Hold
32,000
– – ﹤0.01% 550
2025
Q2 		$66.2K Hold
32,000
– – 0.01% 537
2025
Q1 		$70.4K Buy
+32,000
New +$62.1K 0.01% 510
2024
Q3 		– Sell
-32,000
Closed -$112K – 535
2024
Q2 		$112K Buy
32,000
+12,000
+60% +$36.9K 0.01% 500
2024
Q1 		$55.4K Hold
20,000
– – 0.01% 510
2023
Q4 		$34K Hold
20,000
– – ﹤0.01% 507
2023
Q3 		$20.6K Buy
+20,000
New +$28.5K ﹤0.01% 484

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Wealth Alliance's HRTX Position: Q4 2025 in Review

Wealth Alliance sold out of Heron Therapeutics (HRTX) in Q4 2025, closing a stake of 32,000 shares — an estimated $40.3K sold.

Wealth Alliance first reported a position in HRTX in Q3 2023 and held it in 7 quarters. The position peaked at $112K in Q2 2024. 170 funds tracked by Wall St. Rank hold HRTX as of Q4 2025.

  • Wealth Alliance reported no remaining Heron Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wealth Alliance sold 32,000 Heron Therapeutics shares in Q4 2025, an estimated $40.3K.
  • Wealth Alliance first reported a position in Heron Therapeutics in Q3 2023 and held it in 7 quarters.
  • Wealth Alliance's Heron Therapeutics position peaked at $112K in Q2 2024.
  • 170 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2025.

Based on Wealth Alliance's 13F filing for Q4 2025, filed 13 Feb 2026.